Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
September 3, 2023 2:45 PM 2 min read

Treating PTSD Topically & Directly To The Brain? Psychedelics Delivery Company Poised For Major Breakthrough

by Maureen Meehan Benzinga Editor
Follow
BWVI Logo
BWVIPsycheceutical Bioscience Inc
$0.00030-25.0%
Overview

Psycheceutical Bioscience, Inc (OTCPK: BWVI) is a cutting-edge biotech startup that developed a topical drug delivery system called NeuroDirect, a system that can be used to deliver psychedelic drugs directly to the brain, avoiding the traditional “high” and side effects.

So Far, So Good

If successful, NeuroDirect could have applications for a wide range of neuro-related conditions, including Parkinson’s, drug addiction and traumatic brain injury.

Zapolin, who spoke at the April Benzinga Psychedelics Capital Conference in Miami explained that the company has also received a number of patents for topical back-of-the-neck drug delivery. This approach could be used to deliver dozens of “neuroactive” drugs, from NSAIDS and SSRIs to antipsychotics and pain meds.

Patents for NeuroDirect are owned by a company called DEF, LLC (Defending Everyone’s Freedom), which was founded by a military veteran who paid for and drove the development of the patents, Zapolin told Benzinga recently. 

Nothing Like It In The Medical World: How Does NeuroDirect Work?

NeuroDirect seeks to apply drugs in the form of a patch at the base of the neck, targeting free nerve endings and then triggering nerve impulses that shoot to the spinal cord and brain. “They put it into a crystal structure in the patch and it emits the frequency of psilocin as if you’ve taken a microdose of psilocybin without anything else,” Zapolin explained.

Topical administration, he noted, could be ideal for people who fall into higher-risk categories like teenagers, the elderly or those weary of IV or oral administration. At the moment, nothing like this exists in the medical world, said Zapolin who added that Psycheceutical Bioscience has successfully completed its pre-Investigational New Drug (IND) meeting with the FDA.

Stemming The Opioid Epidemic As Well

While still in the early stages of development, the potential of NeuroDirect is significant. If successful, it could revolutionize the way that drugs are delivered and improve the lives of millions of people, says Zapolin.

If these types of delivery methods become available, they can also play an important role in disrupting the opioid and fentanyl epidemic, which has become one of the country’s worst health crises in history.

“So many of these people are not drug addicts, they’re individuals who had a pain injury, the pills end and then they go to the street and end up buying pills that are laced with fentanyl...and now they’re addicted,” Zapolin concluded.

PharmaVoice also reported on this story.

Photo courtesy of Mike Zapolin

 

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
BiotechCannabisNewsPenny StocksPsychedelicsMarketsGeneral

The company is currently conducting trials in Australia for the treatment of PTSD and complex regional pain syndrome. Earlier this month, Psycheceutical announced the completion of dosing the first cohort of subjects in a Phase I clinical trial of its topical ketamine formulation for PTSD.

Backed by Shark Tank investor Kevin Harrington and led by Mike Zapolin, AKA Zappy, a former Wall Street VP, chief visionary officer and advisor to Psycheceutical.

You will surely hear more about this cutting-edge topic at the Benzinga Cannabis Capital Conference in Chicago on September 27-28 where industry experts from investors, CEOs to cannabis researchers and advocates and everyone in between including Illinois Gov. JD Pritzker will gather. All information is available on bzcannabis.com  

BWVI Logo
BWVIPsycheceutical Bioscience Inc
$0.00030-25.0%
Overview
Comments
Loading...